BioStem Technologies Appoints Katherine Gorrell as Chief Legal & Compliance Officer, Strengthening Leadership for Nasdaq Uplisting

BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Gorrell brings over two decades of experience advising healthcare organizations on regulatory, governance, and growth initiatives, and will oversee BioStem’s legal and compliance functions while playing a central role in enterprise governance.

Gorrell most recently served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, Florida, where she led legal strategy across a complex healthcare enterprise. She previously held roles as General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and advised on operational, regulatory, and strategic matters at Intermountain Healthcare and Providence Health & Services/Swedish Health Services. She holds a JD with Honors in Health Law from the University of Washington School of Law and a BA with Honors in Political Science from the University of Utah.

“Katherine is a key addition to BioStem as we implement our next phase of growth,” said Jason Matuszewski, Chairman and CEO of BioStem Technologies. “Her leadership will support our continued scaling while reinforcing our strong foundation of integrity and compliance, especially as we progress toward a Nasdaq uplisting.”

Gorrell’s appointment comes as BioStem prepares for a Nasdaq uplisting, a move that could increase the company’s visibility and access to capital markets. The company’s current stock trades on the OTC market under the symbol BSEM. Investors can follow developments via the company’s newsroom at https://tinyurl.com/bsemnewsroom.

BioStem Technologies develops and commercializes advanced allograft solutions derived from perinatal tissue, using proprietary processing technologies like BioRetain, CryoTek, and SteriTek. Its products are used across multiple clinical specialties, and its quality management system is accredited by the American Association of Tissue Banks. The company’s portfolio includes brands such as Neox, Clarix, VENDAJE, and American Amnion.

The addition of a seasoned legal and compliance executive signals BioStem’s commitment to strengthening governance as it scales operations and pursues a Nasdaq listing. Gorrell noted, “BioStem is at a pivotal time in its growth and evolution. I look forward to working with the leadership team and board to support sustainable growth and ensure our legal, compliance, and medical affairs functions continue to evolve with the business.”